Analytical Data
-
Gene name
MG281
- Application
-
Alternative Names
MG281；
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P47523
-
Expression Region
1-556aa
-
AA Sequence
MQFKKHKNSVKFKRKLFWTIGVLGAGALTTFSAVMITNLVNQSGYALVASGRSGNLGFKLFSTQSPSAEVKLKSLSLNDGSYQSEIDLSGGANFREKFRNFANELSEAITNSPKGLDRPVPKTEISGLIKTGDNFITPSFKAGYYDHVASDGSLLSYYQSTEYFNNRVLMPILQTTNGTLMANNRGYDDVFRQVPSFSGWSNTKATTVSTSNNLTYDKWTYFAAKGSPLYDSYPNHFFEDVKTLAIDAKDISALKTTIDSEKPTYLIIRGLSGNGSQLNELQLPESVKKVSLYGDYTGVNVAKQIFANVVELEFYSTSKANSFGFNPLVLGSKTNVIYDLFASKPFTHIDLTQVTLQNSDNSAIDANKLKQAVGDIYNYRRFERQFQGYFAGGYIDKYLVKNVNTNKDSDDDLVYRSLKELNLHLEEAYREGDNTYYRVNENYYPGASIYENERASRDSEFQNEILKRAEQNGVTFDENIKRITASGKYSVQFQKLENDTDSSLERMTKAVEGLVTVIGEEKFETVDITGVSSDTNEVKSLAKELKTNALGVKLKL
-
Molecular Weight
65.0 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MG281 is a recombinant protein that has garnered significant attention in the field of biomedical research due to its potential applications in immunotherapy and vaccine development. It is derived from a specific antigenic structure that plays a crucial role in the immune response, particularly in the context of infectious diseases and cancer. The scientific community has focused on MG281 for its ability to stimulate T-cell responses, making it a promising candidate for enhancing immune recognition of tumor cells or pathogens. Furthermore, researchers have been exploring its properties in terms of stability and effectiveness through various purification and expression systems, including yeast and bacterial cell lines. The study of MG281 is grounded in the broader quest to harness recombinant proteins to create effective therapeutic agents and diagnostic tools. By elucidating its structure-function relationships, scientists aim to design improved variants of MG281 that can be used in clinical settings, potentially leading to advancements in personalized medicine. The ongoing investigations into its immunogenicity, safety, and efficacy highlight the importance of MG281 in the development of next-generation therapeutic strategies aimed at combating a range of diseases, thereby contributing to the growing landscape of protein-based therapies in contemporary medicine.
